Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature

Objective: Combination therapy with programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors might be viewed as a promising therapeutic strategy for resistant lung cancer, and it is becoming common that a second PD-1/PD-L1 inhibitor might be used following progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xiuju, Guan, Yaping, Zhang, Bicheng, Liang, Jing, Wang, Baocheng, Li, Yan, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930180/
https://www.ncbi.nlm.nih.gov/pubmed/31921686
http://dx.doi.org/10.3389/fonc.2019.01437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930180/
https://www.ncbi.nlm.nih.gov/pubmed/31921686
http://dx.doi.org/10.3389/fonc.2019.01437

Ejemplares similares